Maren Capital LLC: TMO position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Maren Capital LLC on TMO, newest first. How the timeline and the estimate are built.
Maren Capital LLC held 0 TMO shares at 2025-12-31 per its 13F-HR filed 2026-02-13.
the latest 13F is the newest step
- period ended2025-12-3113F 0 sharesChange vs previous 13F -2,839 shares
13F-HR 0001420506-26-000374 filed by Maren Capital LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2025-09-3013F 2,839 sharesChange vs previous 13F 0 shares
0.08% of the 13F portfolio, value $1,376,972.
13F-HR 0001420506-25-003196 filed by Maren Capital LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-06-3013F 2,839 sharesChange vs previous 13F 0 shares
0.07% of the 13F portfolio, value $1,151,101.
13F-HR 0001941040-25-000482 filed by Maren Capital LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-03-3113F 2,839 sharesChange vs previous 13F -125 shares
0.1% of the 13F portfolio, value $1,412,686.
13F-HR 0001941040-25-000302 filed by Maren Capital LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-12-3113F 2,964 sharesChange vs previous 13F 0 shares
0.12% of the 13F portfolio, value $1,541,962.
13F-HR 0001941040-25-000150 filed by Maren Capital LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-09-3013F 2,964 sharesChange vs previous 13F not available
0.15% of the 13F portfolio, value $1,833,441.
13F-HR 0001941040-24-000519 filed by Maren Capital LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).